Prague Med. Rep. 2023, 124, 444-448
Demonstration of the Rationale for Therapeutic Drug Monitoring of Isavuconazole: A Case Report with a Lung Transplant Recipient
Mucormycosis is a rare invasive fungal disease diagnosed in immunocompromised patients, including those with diabetes or iron overload, and in patients treated for hematological malignancies or after transplantation. Isavuconazole is a triazole antifungal effective against Mucorales with good tolerability, but with potential for relatively high interindividual variability in pharmacokinetics. This report demonstrates the case of a lung transplant recipient treated with isavuconasole that exhibits a very long elimination half-life of 159 hours, and discusses the practical implications of this finding for dosage adjustment and need for therapeutic drug monitoring.
Keywords
Isavuconazole, Antifungals, Pharmacokinetics, Therapeutic drug monitoring, Lung transplant recipient.
Funding
This study was supported by the MH CZ-DRO (University Hospital Motol, Prague, Czech Republic, 00064203), and by the Charles University project Cooperatio (research area PHAR).
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
